Vaxcyte Inc (PCVX)

May 7, 2025, 4:01 PM EDT - 26 days ago

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 8:00 AM EDT - 4 weeks ago

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

Mar 31, 2025, 6:21 PM EDT - 2 months ago

Vaccine stocks fall following FDA resignation

BNTX MRNA NVAX PFE PTCT XBI

Mar 31, 2025, 3:39 PM EDT - 2 months ago

Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity

Mar 31, 2025, 8:56 AM EDT - 2 months ago

Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine

Mar 31, 2025, 7:00 AM EDT - 2 months ago

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

Mar 30, 2025, 5:00 PM EDT - 2 months ago

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

Feb 26, 2025, 3:26 AM EST - 3 months ago

Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 4:01 PM EST - 3 months ago

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 12, 2025, 4:05 PM EST - 3 months ago

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Feb 5, 2025, 8:00 AM EST - 4 months ago

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Jan 30, 2025, 4:05 PM EST - 4 months ago

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 11:51 AM EST - 4 months ago

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

Jan 15, 2025, 7:15 AM EST - 4 months ago

Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy

PFE

Dec 3, 2024, 8:00 AM EST - 6 months ago

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Nov 12, 2024, 7:30 AM EST - 7 months ago

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Nov 5, 2024, 4:01 PM EST - 7 months ago

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 11, 2024, 4:05 PM EDT - 9 months ago

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

Sep 8, 2024, 9:00 AM EDT - 9 months ago

Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027

Sep 6, 2024, 4:05 PM EDT - 9 months ago

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 6, 2024, 3:07 PM EDT - 9 months ago

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy

Sep 6, 2024, 9:07 AM EDT - 9 months ago

Vaxcyte's stock dips after biotech completes $1.42 billion stock offering

Sep 5, 2024, 1:22 AM EDT - 9 months ago

Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high

Sep 4, 2024, 11:58 PM EDT - 9 months ago

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Sep 3, 2024, 4:01 PM EDT - 9 months ago

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Sep 3, 2024, 10:48 AM EDT - 9 months ago

Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data.

Sep 3, 2024, 10:10 AM EDT - 9 months ago

Vaxcyte stock soars 35% on promising VAX-31 vaccine trial results

Sep 3, 2024, 9:24 AM EDT - 9 months ago

Vaxcyte's shares jump on 'promising' early data on pneumococcal vaccine

Sep 3, 2024, 8:51 AM EDT - 9 months ago

Vaxcyte's stock soars 33% after trial shows positive data for pneumococcal vaccine

Sep 3, 2024, 7:07 AM EDT - 9 months ago

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Sep 2, 2024, 6:40 PM EDT - 9 months ago

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Jul 2, 2024, 8:30 AM EDT - 1 year ago

Vaxcyte Appoints John Furey to Board of Directors

May 8, 2024, 4:05 PM EDT - 1 year ago

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 2, 2024, 4:05 PM EDT - 1 year ago

Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 4, 2024, 8:30 AM EST - 1 year ago

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

Feb 28, 2024, 12:32 AM EST - 1 year ago

Vaxcyte, Inc. (PCVX) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 4:01 PM EST - 1 year ago

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 15, 2024, 4:05 PM EST - 1 year ago

Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Feb 2, 2024, 6:39 PM EST - 1 year ago

Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 1, 2024, 4:05 PM EST - 1 year ago

Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 30, 2024, 11:37 PM EST - 1 year ago

Vaxcyte Announces Pricing of $750 Million Public Offering

Jan 29, 2024, 8:30 AM EST - 1 year ago

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

Jan 16, 2024, 4:01 PM EST - 1 year ago

Vaxcyte Appoints Whitney Jones as Chief People Officer

Jan 4, 2024, 4:01 PM EST - 1 year ago

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

Dec 4, 2023, 6:35 PM EST - 1 year ago

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Nov 28, 2023, 8:30 AM EST - 1 year ago

Vaxcyte Appoints Jacks Lee to Board of Directors

Nov 27, 2023, 4:00 PM EST - 1 year ago

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

Nov 9, 2023, 8:30 AM EST - 1 year ago

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Nov 6, 2023, 4:03 PM EST - 1 year ago

Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update